BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rukobia (Fostemsavir) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rukobia (Fostemsavir)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07053384-963@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20270122
DTEND;VALUE=DATE:20270123
SUMMARY:Rukobia (Fostemsavir): Phase 1 readout est. (NCT07053384)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 1\, HIV.\nStudy: A Study to Inves
 tigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce th
 e Size and Activity of the Viral Reservoir in People Living With HIV\nEsti
 mated primary completion: 22 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fostemsavir#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07053384
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030920-963@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rukobia (Fostemsavir): Phase 2 readout est. (NCT07030920)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 2\, HIV.\nStudy: Reducing Systemi
 c Inflammation in People on Antiretroviral Therapy\nEstimated primary comp
 letion: October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fostemsavir#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07030920
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04648280-963@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rukobia (Fostemsavir): Phase 1/2 readout est. (NCT04648280)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 1/2\, HIV.\nStudy: Safety and Pha
 rmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children
  and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class
  Antiretroviral Resistance\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fostemsavir#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04648280
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-963@assetmemo.bio
DTSTAMP:20261121T005433Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Rukobia (Fostemsavir): Phase 3 readout est. (NCT07393659)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 3\, HIV.\nStudy: A Continued Acce
 ss Study for Participants Transitioning From ViiV Healthcare-sponsored or 
 ViiV Healthcare-collaborative Parent Studies for HIV Treatment\nEstimated 
 primary completion: 14 September 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fostemsavir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07393659
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
